Bolt Biotherapeutics (NASDAQ:BOLT) Announces Earnings Results

Bolt Biotherapeutics (NASDAQ:BOLT) issued its quarterly earnings results on Tuesday. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04), Zacks reports. Bolt Biotherapeutics had a negative return on equity of 64.49% and a negative net margin of 665.56%. The company had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $1.02 million.

Bolt Biotherapeutics Price Performance

BOLT stock traded down $0.01 during trading on Wednesday, hitting $0.63. 56,233 shares of the company traded hands, compared to its average volume of 165,353. The stock’s 50-day simple moving average is $0.64 and its 200 day simple moving average is $0.74. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.19. Bolt Biotherapeutics has a 1 year low of $0.55 and a 1 year high of $1.56.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $3.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.